Publications

Manuscripts

  • Wenzler E, Bleasdale SC, et al. Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants (PROOF). Antimicrob Agents Chemother. Epub 2018 Jun 11.
  • Papp-Wallace KM, Barnes MD, et al. Relebactam is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores the Susceptibility of Imipenem Against KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00174-18. doi: 10.1128/AAC.00174-18.
  • Miller WR, Seas C, et al. The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123.
  • Patel R, Fang FC. Diagnostic Stewardship: Opportunity for a Laboratory-Infectious Diseases Partnership. Clin Infect. Epub 2018 Mar 14.
  • Shin WS, Bergstrm, et al. Discovery of 1-Hydroxypyridine-2(1H)-thione-6-carboxylic Acid as aFirst-in-Class Low-Cytotoxic Nanomolar Metallo beta-Lactamase Inhibitor. ChemMedChem. 2017 Jun 7;12(11):845-849. doi: 10.1002/cmdc.201700182.
  • Chotiprasitsakul D, Han JH, et al. Comparing the Outcomes of Adults with Enterobacteriaceae Bacteremia Receiving Short-Course versus Prolonged-Course Antibiotic Therapy in a Propensity-Score Matched Multicenter Cohort. Clin Infect Dis. 2018 Jan 6;66(2):172-177. doi: 10.1093/cid/cix767.
  • van Duin D, Lok J, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
  • Eilertson B, Cober E, et al. Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. Open Forum Infect Dis.  2017 Oct 6;4(4):ofx216. doi: 10.1093/ofid/ofx216.
  • Nielsen TB, Pantapalangkoor P, et al. Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. MBio. 2017 Aug 22;8(4). pii: e00818-17.
  • Henig O, Cober E, et all. A Prospective Observational Study of the Epidemiology, Management and Outcomes of Skin and Soft Tissue Infections due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infect Dis. Epub 2017 Jul 27.
  • Thom KA, Rock C, et al. Factors Leading to Transmission Risk of Acinetobacter baumannii. Crit Care Med. 2017 Jul;45(7):e633-e639. doi: 10.1097/CCM.0000000000002318.
  • Martirosov DM, Bidell MR, et al. Relationship Between Vancomycin Exposure and Outcomes Among Patients with MRSA Bloodstream Infections With Vancomycin Etest® MIC Values of 1.5-2 mg/L. Diagn Microbiol Infect Dis.  2017 Jul 1;88(3):259-263.
  • Rojas LJ, Hujer AM, et al. NDM-5 and OXA-181 Beta-Lactamases, a Significant Threat Continues To Spread in the Americas. Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00454-17. doi: 10.1128/AAC.00454-17. Print 2017 Jul.
  • Thaden JT, Park LP, et al. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria. Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02671-16.
  • Evans SR, Harris AD. Methods and Issues in Studies of CRE. Virulence. 2017 May 19;8(4):453-459. doi: 10.1080/21505594.2016.1213473.
  • Ochiai T, Hamasaki T, et al. Group-Sequential Three-Armnoninferiority Clinical Trial Designs. J Biopharm Stat. 2017 Apr 17.
  • Marshall S, Hujer AM, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome ?-Lactam Resistance Conferred by Metallo-?-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02243-16.
  • Chambers HF, Cross HR, et al. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. Clin Infec Dis.  2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824.
  • Anderson DJ, Jenkins TC, et al. The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. Clin Infec Dis. 2017 Mar 15;64(suppl_1):S36-S40. doi: 10.1093/cid/ciw830.
  • Murray BE, Jezek A. The Antibacterial Resistance Leadership Group: First Steps. Clin Infect Dis. 2017; 64 (suppl_1): S1-S2. doi: 10.1093/cid/ciw8.
  • Cross HR, Harris A, et al. Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64 (suppl_1): S8-S12. doi: 10.1093/cid/ciw825.
  • Manca C, Hill C, et al. Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64 (suppl_1): S13-S17. doi: 10.1093/cid/ciw826.
  • Huvane J, Komarow L, et al. Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64 (suppl_1): S18-S23. doi: 10.1093/cid/ciw827.
  • Doernberg SB, Lodise TP, et al. Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64 (suppl_1): S24-S29. doi: 10.1093/cid/ciw828.
  • Doi Y, Bonomo RA, et al. Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64 (suppl_1): S30-S35. doi: 10.1093/cid/ciw829.
  • Tsalik EL, Petzold E, et al. Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017 Mar 15; 64 (suppl_1): S41-S47. doi: 10.1093/cid/ciw831.
  • Rojas LJ, Salim M, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clin Infect Dis. 2017 Mar 15;64(6):711-718. doi: 10.1093/cid/ciw805.
  • Evans SR, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?. Stat Commun Infect Dis.  2017 Mar 14;9(1). pii: 20160003.
  • Shields RK, Chen S, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02097-16.
  • Haidar G, Clancy CJ et al. Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum ?-Lactamases. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02097-16.
  • Viau RA, Kiedrowski, et al. A Comparison of Molecular Typing Methods Applied to Enterobacter cloacae complex: hsp60 Sequencing, Rep-PCR, and MLST. Pathog Immun. 2017;2(1):23-33. doi: 10.20411/pai.v2i1.99. Epub 2017 Feb 1.
  • Patel R, Tsalik EL, et al. Viewpoint: MASTERMIND – Bringing Microbial Diagnostics to the Clinic. Clin Infect Dis.  2017 Feb 1;64(3):355-360. doi: 10.1093/cid/ciw788.
  • Wong D, Nielsen TB, et al. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev. 2017 Jan;30(1):409-447
  • Evans SR, Hujer AM, et al. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics (RMDs) to Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. PRIMERS III. J Clin Microbiol. 2016 Dec 28;55(1):134-144. doi: 10.1128/JCM.01524-16.
  • Thompson GR 3rd, Rendon A, et al.  Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis. 2016 Dec 15;63(12):1619-1621. Epub 2016 Sep 13.
  • Spellberg B, Bonomo RA. Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: ”We’re Gonna Need a Bigger Boat” Clin Infect Dis. 2016 Dec 15;63(12):1619-1621. Epub 2016 Sep 13.
  • Spellberg B, Gibert DN. The Rise of Fluoroquinolone-Resistant Escherichia coli in the Community: Scarier Than We Thought. Clin Infect Dis. 2015 Dec 15;212(12):1853-5.
  • Evans SR, Follmann D. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation.  Stat Biopharm Res. 2016 Dec 12;8(4):386-393.
  • Pennello G, Pantoja-Galicia N, et al. Comparing diagnostic tests on benefit-risk. J Biopharm Stat. 2016 Dec 1;26(6):1083-1097.
  • Banerjee R, Ozenci V, et al. Viewpoint: Individualized Approaches Are Needed for Optimized Blood Cultures. Clin Infect Dis. 2016 Nov 15;63(10):1332-1339.
  • Pana ZD, Seidel D, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016 Nov 10;16(1):66.
  • Mills JP, Wilck MB, et al. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen. Transpl Infect Dis. 2016 Oct;18(5):777-781.
  • Spellberg B, Barlett JG, et al. How to Pitch an Antibiotic Stewardship Program to the Hospital C-Suite. Open Forum Infect Dis. 2016 Oct 15;3(4):ofw210. eCollection 2016 Oct.
  • Patel R. New Developments in Clinical Bacteriology Laboratories. Mayo Clin Proc. 2016 Oct 1;91(10):1448-1459. doi: 10.1016/j.mayocp.2016.06.020. Epub 2016 Aug 21.
  • Cornely OA, Vehreschid MJ. Editorial Commentary: Where to Place the New Treatments for Clostridium difficile Infection? Clin Infect Dis. 2016 Sep 15; 15;63(6):735-6.
  • Spellberg B. The New Antibiotic Mantra-”Shorter Is Better’ JAMA Intern Med. 2016 Sep 1; 176(9): 1254–1255.
  • van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation ?-Lactam/?-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016 Jul 15;63(2):234-41.
  • Evans S, Kreiswirth B, et al. Reply to Lesho and Clifford: “In the Eye of a Storm”: The Goal of Rapid Molecular Diagnostics in PRIMERS I and II. Clin Infect Dis. 2016 May 25. pii: ciw336.
  • Evans S, Pennello G, et al. Benefit-Risk Evaluation for Diagnostics: a   Framework (BED-FRAME).Clin Infect Dis. 2016 July; 63 (6): 812-817. doi: 10.1093/cid/ciw329. Epub 2016 May 18.
  • Goodman KE, Lessler J, et al. A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase–Producing Organism. Clin Infect Dis. 2016 July; doi: 10.1093/cid/ciw425. Epub 2016 June 28.
  • Hauck C, Cober E, et al.  Spectrum of Excess Mortality due to Carbapenem-Resistant Klebsiella pneumoniae Infections. Clin Microbiol Infect. 2016 Jun:22(6):513-9.
  • Farowski F, Cornely OA, et al. High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro. Antimicrob Agents Chemother. 2016 May 23;60(6):3533-9.
  • Evans S, Follman D, et al. Reply to Phillips, Morris, and Walker. Clin Infect Dis. 2016 Mar 15;62(6):815-6.
  • Wright MS, lovleva A, et al. Genome Dynamics of Multidrug-resistant Acinetobacter baumannii during Infection and Treatment. Genome Med. 2016 Mar 3;8(1):26. doi: 10.1186/s13073-016-0279-y.
  • Thaden JT, Keller AE, et al. Pseudomonas aeruginosa Bacteremic Patients Exhibit Non-Protective Antibody Titers against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide. J Infect Dis. 2016 Feb 15. 213(4):640-8.
  • Messina JA, Thaden JT, et al. Impact of Bacterial and Human Genetic Variation on Staphylococcus aureus Infections. PLoS Pathogens. 2016 Jan 14;12(1):e1005330.
  • Tsalik EL, Henau R, et al. Host Gene Expression Classifiers Diagnose Acute Respiratory Illness Etiology. Sci Transl Med. 2016 Jan 20;8(322):322ra11.
  • Messina JA, Cober E, et al. Hospital Readmissions in Patients with Carbapenem-Resistant Klebsiella 1 pneumonia. Infect Control Hosp Epidemiol. 2015 Dec 21:1-8.
  • Evans SR, Follmann D.Fundamentals and Innovation in Antibiotic Trials. Stat Biopharm Res. 2015;7(4):331-336.
  • Ericson JE, Popoola VO, et al. Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants. JAMA Pediatr. 2015;169(12):1105-1111.
  • Banerjee R, Teng C, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015 Oct 1;61(7):1071-80. doi: 10.1093/cid/civ447. Epub 2015 Jul 20.
  • Choe H, Narayanan AS, et al. Immunomodulatory Peptide IDR-1018 Decreases Implant Infection and Preserves Osseointegration. Clin Orthop Relat Res. 2015 Sep 30;473(9):2898-907.
  • Evans S, Hujer AM, et al.  Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clin Infect Dis. 2015 Sep 25. pii: civ837. [Epub ahead of print].
  • Khatri A, Naeger MN, et al. Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015 Aug 31;59(8):4375-8. doi: 10.1128/AAC.00553-15.
  • Bergin SP, Thaden J, et al. Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy. Pediatr Infect Dis J. 2015 Aug 31;34(9):933-936.
  • van Duin, Cober E, et al. Residence in Skilled Nursing Facilities is associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2015 Aug;36(8):942-8.
  • Uno H, Wittes J, et al.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015 Jul 21;163(2):127-34.
  • Banerjee R, Teng C, et al. Randomized Trial of Rapid Multiplex PCR-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. Epub (preprint) 2015 July 20.
  • Evans SR, Rubin D, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Days of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Jun 25. pii: civ495. Epub 2015 Jun 25.
  • Ando Y, Hamasaki T, et al. Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts. Stat Biopharm Res. 2015 Jun 24;7(2):81-94.
  • Messina JA, Fowler VG Jr, et al. Oritavancin for Acute Bacterial Skin and Skin Structure Infections. Expert Opin Pharmacother. 2015 May 17;16(7):1091-8.
  • Evans S, Hujer AM, et al. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clin Infect Dis. 2015 Apr;34(4):371-5.
  • Hamasaki T, Asakura K, et al. Group-sequential Strategies in Clinical Trials with Multiple Co-primary Outcomes. Stat Biopharm. 2015 Apr;2015;7(1):36-54.
  • Ericson JE, Thaden J, et al. No Survival Benefit with Empirical Vancomycin Therapy for Coagulase-negative Staphylococcal Bloodstream Infections in Infants.  Pediatr Infect Dis J.  2015 Apr;34(4):371-5.
  • van Duin, Cober E, et al. Impact of Therapy and Strain Type on Outcomes in Urinary Tract Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Chemother. 2015 Apr 1;70(4):1203-11.
  • Spellberg B, Barlett J, et al. Novel Approaches Are Needed to Develop Tomorrow’s Antibacterial Therapies.  Am J Respir Crit Care Med. 2015 Jan 15;191(2):135-40.
  • Tamma PD, Han JH, et al. Carbapenem Therapy is Associated with Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum β-Lactamase Bacteremia. Clin Infect Dis. 2015 Jan 13. pii: civ003. Epub ahead of print.
  • Wright MS, Suzuki Y, et al. Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae Reveal Multiple Pathways of Resistance. Antimicrob Agents Chemother. 2015 Jan;59(1):536-43. doi: 10.1128/AAC.04037-14. Epub 2014 Nov 10.
  • van Duin D, Cober E, Richter SS, et al. Tigecycline Therapy for Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Bacteriuria Leads to Tigecycline Resistance. Clin Microbiol Infect. 2014 Dec; 20(12):O1117-20. doi: 10.1111/1469-0691.12714. [Epub ahead of print].
  • Vazquez Melendez EL, Farrell JJ, et al. Culture Negative Empyema in A Critically Ill Child: An Opportunity for Rapid Molecular Diagnostics. BMC Anesthesiol. 2014 Nov 22;14:107. doi: 10.1186/1471-2253-14-107. eCollection 2014.
  • Perez F, Adachi J, Bonomo RA. Antibiotic-Resistant Gram-Negative Bacterial Infections in Patients with Cancer. Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S335-9. doi: 10.1093/cid/ciu612.
  • Stafford KA, Boutin M, Evans SR, et al.Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies. Clin Infect Dis. 2014 Oct 15;59(8):1142-7. doi: 10.1093/cid/ciu486. Epub 2014 Jun 30.
  • Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014 Oct 1;312(13):1330-41.doi: 10.1001/jama.2014.9743.
  • Perez F, Hujer AM, et al. Extensively Drug-Resistant Pseudomonas Aeruginosa Isolates Containing blaVIM-2 and Elements of Salmonella Genomic Island 2: A New Genetic Resistance Determinant in Northeast Ohio. Antimicrob Agents Chemother. 2014 Oct;58(10):5929-35. doi: 10.1128/AAC.02372-14. Epub 2014 Jul 28.
  • David MZ, Daum RS, et al. Staphylococcus aureus Bacteremia at Five U.S. Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections. Clin Infect Dis. 2014 Sep15;59(6):798-807 doi: 10.1093/cid/ciu410 Epub 2014 May 30.
  • Spellberg B, Gibert DN. The Future of Antibiotics and Resistance: A Tribute to a Career of Leadership by John Bartlett. Clin Infect Dis. 2014 Sep 15;59 Suppl 2:S71-5. doi: 10.1093/cid/ciu392.
  • Nagalingam S, Lisgaris M, et al. Identification of Occult Fusobacterium Nucleatum Central Nervous System Infection By Use of PCR-Electrospray Ionization Mass Spectrometry. J Clin Microbiol. 2014 Sep;52(9):3462-4. doi: 10.1128/JCM.01082-14. Epub 2014 Jun 25.
  • Wright MS, Perez F, Brinkac L, et al. Population Structure of KPC-producing Klebsiella pneumoniae from Midwestern US Hospitals. Antimicrob Agents Chemother. 2014 Aug;58(8):4961-5. doi: 10.1128/AAC.00125-14. Epub 2014 Jun 9.
  • van Duin D, Perez F, Rudin SD, et al. Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network. Antimicrob Agents Chemother. 2014 Jul;58(7):4035-4041. Epub 2014 May 5.
  • Asakura K, Hamasaki T, Sugimoto T, et al. Sample size determination in group-sequential clinical trials with two co-primary endpoints. Stat Med. 2014 Jul 30;33(17):2897-913. doi: 10.1002/sim.6154. Epub 2014 Mar 27.
  • Spellberg B. The Future of Antibiotics. Crit Care. 2014 Jun 27;18(3):228. doi: 10.1186/cc13948.
  • Ramirez MS, Xie G, Johnson S, et al. Genome Sequences of Two Carbapenemase-Resistant Klebsiella pneumoniae ST258 Isolates. Genome Announc. 2014 Jun 19;2(3). pii: e00558-14. doi: 10.1128/genomeA.00558-14.
  • Chambers HF, Barlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun;58(11):1571-6. doi: 10.1093/cid/ciu132. Epub 2014 Mar 6.
  • Tugal D, Lynch M, et al. Multi-Drug-Resistant Klebsiella pneumoniae Pancreatitis: A New Challenge in a Serious Surgical Infection. Surg Infect (Larchmt). 2014 May 21 [Epub ahead of print].
  • Perez F, Bonomo RA. Vaccines for Acinetobacter baumannii: Thinking “Out of the Box”. Vaccine. 2014 May 7;32(22):2537-9.
  • Fowler VG Jr, Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75. doi: 10.1111/1469-0691.12570.
  • Spellberg B. Antibiotic Judo: Working Gently with Prescriber Psychology to Overcome Inappropriate Use. JAMA Intern Med. 2014 Mar;174(3):432-3. doi: 10.1001/jamainternmed.2013.14019.
  • Perez F, Rudin SD, et al. OqxAB, a quinolone and olaquindox efflux pump, is widely distributed among multidrug-resistant Klebsiella pneumoniae isolates of human origin. Antimicrob Agents Chemother. 2013 Sep;57(9):4602-3.

Abstracts

  • Banerjee R, Dylla B, et al. Accelerate Pheno System (AXDX) performance during a randomized clinical trial evaluating rapid identification and antimicrobial susceptibility testing for Gram negative bacteremia (RAPIDS-GN). Presented at ASM Microbe June 2018.
  • Lisaa MA, Shah D, et al. Intestinal Microbiome Shows Altered Diversity and Enterobacteriaceae Overgrowth in Carriers of Fluoroquinolone Resistant E. Coli. Presented at AUA May 2018.
  • Wenzler E, Meyer K, et al. In vitro Susceptibility Testing of Fosfomycin Does Not Predict in vivo Urinary Antibacterial Activity. Presented at ECCMID April 2018.
  • Wenzler E, Meyer K, et al. Ex vivo Urinary Pharmacodynamics of Fosfomycin Against 5 Typical Uropathogens After 5 Daily Doses. Presented at ECCMID April 2018.
  • Khine AA, Samiei A, et al. Evaluation of Qvella’s FAST™ HR Process for Early Identification of Viral Infections by Detection of Host Response Biomarkers. Presented at ECCMID April 2018.
  • Doernberg SB, Paul M, et al. Desirability of Outcome Ranking (DOOR) Analysis of Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (BSIs) From a Trial Comparing TrimethoprimSulfamthoxazole Versus Vancomycin. Presented at ECCMID April 2018.
  • van Duin D, Humphries R, et al. Ceftazidime/avibactam Susceptibility Patterns in Carbapenem-Resistant Enterobacteriaceae in the US: Results from the Consortium on Resistance against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE-2). Presented at ID Week October 2017. Presented at ID Week October 2017.
  • Wenzler E, Bleasdale SC, et al. Phase I Study to Evaluate the Pharmacokinetics of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. In vitro Activity of Fosfomycin Alone and Combined with Cefepime and Meropenem Against Carbapenemase-Producing Gram-Negative Bacteria. Presented at ID Week October 2017.
  • Bleasdale SC, Wenzler E, et al. Phase I Study to Evaluate the Safety and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Presented at ID Week October 2017.
  • Wiederhold NP, Jorgensen JH, et al.  In vitro Activity of Fosfomycin Alone and Combined with Cefepime and Meropenem Against Carbapenemase-Producing Gram-Negative Bacteria. Presented at ID Week October 2017.
  • van Duin D, Arias c, et al. National Variability in Patients with Carbapenem-resistant Enterobacteriaceae in the US; First results from CRACKLE-2. Presented at ASM Microbe June 2017.
  • Boshe A, Cober E, et al. Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-resistant Enterobacteriaceae. Presented at ASM Microbe June 2017.
  • Wright MS, Rojas CL, et al. Multiscale Patterns Of Carbapenem-Resistant Klebsiella Pneumoniae Diversity Across CRACKLE Consortium Sites in the USA. Presented at ASM Microbe June 2017.
  • Karichu J, Otiso J, et al. Evaluation of a Broth Microdilution Plate for Determining the Susceptibility of Carbapenem-resistant Klebsiella pneumoniae to Polymixins. Presented at ASM Microbe June 2017.
  • Montgomery J, Nawrocki J, et al. Rapid Discrimination of Viral and Bacterial Infections by Host Transcriptomic Analysis Using the FilmArray® System. Presented at ASM Microbe June 2017.
  • Evans S, Tran TT, et al. “Promise and Peril”: Rapid Molecular Diagnostics (RMDs) and Clinical Decision-Making in Infectious Diseases. Presented at ECCMID April 2017.
  • Rojas LJ, Cober E, et al. Molecular Analysis of Colistin Resistance among Klebsielle pneumoniae Producing KPC (Kp-KPC): Heterogeneity of Genetic Mechanisms. Presented at ID Week October 2016.
  • Nguyen MH, Shields RK, et al. Impact of Rectal Colonization with Highly Drug-resistant Enterobacteriaceae on Post-transplant Infections: The Carbapenem Resistant Enterobacteriaceae Carriage in Solid Organ Transplant (CREST) Study. Presented at ID Week October 2016.
  • Henig O, van Duin, et at. Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) due to Carbapenem Resistant Enterobacteriaceae: A Report from The Consortium on Resistance against Carbapenems in Klebsiella. pneumoniae (CRaCKle). Presented at ID Week October 2016.
  • Evans SR, Tran T, et al. Choosing Ceftazidime/Avibactam and Ceftolozane/Tazobactam as Empiric Therapies against Pseudomonas aeruginosa (Pa) using Rapid Molecular Diagnostics (RMDs): PRIMERS IV. Presented at ID Week October 2016.
  • Doernberg S, Gouskova N, et al. BAC DOOR: A Clinician Ranking Exercise for Better S. aureus Bacteremia Trial Design. Presented at ID Week October 2016.
  • Anderson DJ, Watson S, et al. Feasibility Assessment of Stewardship Interventions in Community Hospitals: a Multicenter, 3-Stage Cluster-Randomized Historically Controlled Crossover Trial. Presented at ID Week September 2016.
  • van Duin D, Cober E, et al. Colistin versus Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Presented at ECCMID April 2016.
  • Holland T, Mikita S, et al. Streamlining Antibacterial Drug Development Programs to Address Unmet Medical Need: Patient and Provider Attitudes on a Modified Benefit-Risk Calculus. Presented at ATS May 2016.
  • Jacobs MR, Hujer AM, et al. Antimicrobial Susceptibility of Carbapenem-Susceptible and -Resistant Acinetobacter baumannii (Ab): PRIMERS-III, part 1. Presented at ID Week October 2015.
  • Salim M, Perez, F et al. Colistin Resistance in Patients with Carbapenem-resistant Klebsiella pneumoniae is Associated with Increased Mortality. Presented at ID Week October 2015.
  • Evans S, Jiang H, et al. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics (RMDs) to Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. PRIMERS-III. Presented at ID Week October 2015.
  • Evans S, Jiang H, et al. Benefit:Risk Evaluation in Diagnostics: An Example Comparing Two Rapid Molecular Diagnostics Testing Imipemem Susceptibility in Acinetobacter spp. Presented at ID Week October 2015.
  • van Duin D, Perez F et al. The Spectrum of Attributable Mortality due to Carbapenem-Resistant Klebsiella pneumoniae (CRKp). Presented at ICAAC September 2015 and ID Week October 2015.
  • van Duin D, Perez F et al. The Movement of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) among Healthcare Facilities: A Network Analysis. Presented at ID Week October 2015.
  • Domitrovic TN, Hujer AM, et al. Is It Time to Identify Acinetobacter spp. by Molecular Methods Only? Presented at ID Week October 2015.
  • Ramirez M, Xie G, et al. Genomic comparison of carbapenem-resistant Klebsiella pneumoniae ST258 strains isolated from an emerging outbreak in Northeast Ohio. Presented at ICAAC September 2015.
  • Hill C, Manca C, et al. A Novel Research Resource: Virtual Bacteria Strain Repository. Presented at ICAAC September 2015.
  • Banerjee R, Teng C, et al. Randomized Trial of Blood Culture Pathogen Identification Using the FilmArray Blood Culture ID Panel (BCID) vs. Standard Culture Techniques: Impact on Antimicrobial Use and Outcomes. Presented at ICAAC September 2014.
  • Adams MD, Wright M, Marshall S, et al. Genetic Analysis of Colistin Resistance Using RNAseq in Klebsiella pneumonia. Presented at ICAAC September 2014.
  • Khatri A, Naeger Murphy N, Wiest P, et al. Pyelonephritis In pregnancy caused by carbapenem-resistant Enterobacteriaceae (CRE): an emerging community infection? Presented at ICAAC September 2014.
  • Messina J, Cober E, Richter SS, et al. Use of Tigecycline in Patients with Carbapenem-resistant Klebsiella pneumoniae (CRKP) is Associated with Increased Risk for Readmissions with CRKP. Presented at ID Week October 2014.
  • Perez F, Rudin SD, Cober E et al. Temporal trends among ST258 Klebsiella pneumoniae strains harboring blaKPC (KPC-Kp) in the Great Lakes region: insights from molecular surveillance. Presented at ICAAC September 2014.
  • Ramirez M, Johnson S, Xie G, et al. Whole-genome Sequence Comparison of Two Carbapenem-resistant ST258 Klebsiella pneumoniae Strains Reveals Potential Markers for Clinical and Epidemiologic Identification in the HHZ Region. Presented at ICAAC September 2014.
  • Thaden JT, Ericson JE, Cross H, et al. Survival Benefit of Empirical Vancomycin Therapy for Staphylococcus aureus Bloodstream Infections in Infants. Presented at ICAAC September 2014.
  • van Duin D, Cober E, Richter SS, et al. Community Origin and Mortality in Pneumonia Caused by Carbapenem-Resistant Klebsiella pneumoniae. Presented at ID Week October 2014.
  • van Duin D, Perez F, Ruding SD, et al. Impact of ST258 Klebsiella pneumoniae harboring KPC in the Great Lakes region: insights from the Consortium on Resistance against Carbapenems in K. pneumonia (CRaCKle). Presented at ICAAC September 2014.
  • Hujer AM, Evans S, Jiang H, et al. Can Rapid Molecular Diagnostics Assist in the Choice of b-Lactam Antibiotics? An Analysis of Data from PRIMERS-II of the Antibiotic Resistance Leadership Group (ARLG). Presented October 2014, ID Week 2014.
  • Ericson JE, Hornik CP, Thaden J, et al. Empirical Vancomycin Therapy for Coagulase-Negative Staphylococcal Sepsis in Infants. Presented at PAS  May 2014.
  • Hujer AM, Evans SR, Jiang H, et al. Can Rapid Molecular Diagnostics Assist in the Choice of Beta-Lactam Antibiotics? An Analysis of Data from PRIMERS-I. Presented at ECCMID May 2014.
  • Banerjee R, Teng C, et al. Clinical and Economic Impact of Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles. Presented at Translational Science April 2014.
  • van Duin, Cober E, et al. Risk for Readmissions in Hospitalized Patients with Carbapenem-Resistant Klebsiella pneumonia. Presented at ID WEEK October 2013.
  • Hujer AM, Hujer KM, Jacobs M, et al. Using Molecular Diagnostics to Decipher the Genetic Basis of Antibiotic Resistance in Clinical Isolates of Gram-Negative Bacteria. [Abstract 42292]. Poster presentation at ID Week 2013. October 2013.
  • van Duin, Perez F, et al. Molecular and Clinical Correlation in Carbapenem-resistant Klebsiella pneumonia (CR-Kp). Establishment of a Surveillance Network in Northeast Ohio (NeOSuN).  Presented at ID Week October 2012.